PharmAla Biotech Holdings, Inc. (TSE:MDMA) has released an update.
PharmAla Biotech Holdings Inc. has partnered with the University of Texas, San Antonio, to supply a unique dosage form of their proprietary LaNeo™ MDMA for a clinical trial. Additionally, the company has announced the publication of a patent application for APA-01, a new molecular entity, signaling growth in their intellectual property portfolio.
For further insights into TSE:MDMA stock, check out TipRanks’ Stock Analysis page.
